EA201991810A1 - HEMISULPHATE NUCLEOTIDE SALT FOR TREATMENT OF HEPATITIS C VIRUS - Google Patents

HEMISULPHATE NUCLEOTIDE SALT FOR TREATMENT OF HEPATITIS C VIRUS

Info

Publication number
EA201991810A1
EA201991810A1 EA201991810A EA201991810A EA201991810A1 EA 201991810 A1 EA201991810 A1 EA 201991810A1 EA 201991810 A EA201991810 A EA 201991810A EA 201991810 A EA201991810 A EA 201991810A EA 201991810 A1 EA201991810 A1 EA 201991810A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis
treatment
hemisulphate
virus
nucleotide salt
Prior art date
Application number
EA201991810A
Other languages
Russian (ru)
Inventor
Адель Мусса
Жан-Пьер Соммадосси
Original Assignee
Atea Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atea Фармасьютикалс, Инк. filed Critical Atea Фармасьютикалс, Инк.
Priority claimed from PCT/US2018/016301 external-priority patent/WO2018144640A1/en
Publication of EA201991810A1 publication Critical patent/EA201991810A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Гемисульфатная соль структурыдля лечения хозяина, инфицированного гепатитом C, а также ее фармацевтические композиции и лекарственные формы, в том числе твердые лекарственные формы.Hemisulfate salt structure for the treatment of a host infected with hepatitis C, as well as its pharmaceutical compositions and dosage forms, including solid dosage forms.

EA201991810A 2017-10-20 2018-01-31 HEMISULPHATE NUCLEOTIDE SALT FOR TREATMENT OF HEPATITIS C VIRUS EA201991810A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762575248P 2017-10-20 2017-10-20
PCT/US2018/016301 WO2018144640A1 (en) 2017-02-01 2018-01-31 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

Publications (1)

Publication Number Publication Date
EA201991810A1 true EA201991810A1 (en) 2020-01-09

Family

ID=69374511

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991810A EA201991810A1 (en) 2017-10-20 2018-01-31 HEMISULPHATE NUCLEOTIDE SALT FOR TREATMENT OF HEPATITIS C VIRUS

Country Status (1)

Country Link
EA (1) EA201991810A1 (en)

Similar Documents

Publication Publication Date Title
CO2019009215A2 (en) Hemi-sulfate nucleotide salt for the treatment of hepatitis C virus
EA201791886A1 (en) ANTI-VIRUS CONNECTIONS
EA201790630A1 (en) METHODS OF OBTAINING RIBOSIDS
PH12017501598A1 (en) �-D-2`-DEOXY-2`a-FLUORO-2`-�-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
EA201890999A1 (en) VACCINE AGAINST VIRUS HERPES VIRUS
EA201592126A1 (en) 6-BRIDGED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
CL2016002179A1 (en) New 6-fused heteroaryl dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection.
EA201691261A1 (en) NEW DIHYDROCHINOLYSINES FOR THE TREATMENT AND PREVENTION OF INFECTION CAUSED BY THE HEPATITIS B VIRUS
EA201490588A1 (en) METHODS OF TREATMENT OF HEPATITIS C VIRUS
CY1125163T1 (en) 2'-N6-Substituted Purine Nucleotides for RNA Virus Therapy
EA201892216A1 (en) SUBSTITUTED INDIN DERIVATIVES AS AN INHIBITORS OF DENG VIRUS REPLICATION
EA201892219A1 (en) SUBSTITUTED INDIN DERIVATIVES AS AN INHIBITORS OF DENG VIRUS REPLICATION
EA201592184A1 (en) 4'-FLUOR-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES
EA201890454A1 (en) PYRROPHYRIMIDINE NUCLEOSIDE AND THEIR ANALOGUES THAT CAN BE USED AS ANTI-VIRUS MEANS
EA201892214A1 (en) SUBSTITUTED DERIVATIVES OF INDOL AS AN INHIBITORS OF DENG VIRUS REPLICATION
EA201690687A1 (en) REPLICATION INHIBITORS OF THE VIRUS OF IMMUNODEFICIENCY
EA201792008A1 (en) COMPOUNDS OF AZAPIRIDON AND METHODS OF THEIR APPLICATION
EA201791614A1 (en) INDOL DERIVATIVES AS AN INHIBITORS OF DENGE VIRUS REPLICATION
EA201892246A1 (en) DERIVATIVES OF AMINOTHIAZOLE OBTAINED AS ANTI-VIRUS AGENTS
EA201591397A1 (en) CINOXALINONES AND DIHYDROCHINOXALINONS AS ANTI-VIRUS MEANS AGAINST RESPIRATORY-SYNCYTIAL VIRUS
EA201791807A1 (en) NEW TRITERPENON WITH C-3 WITH REVERSE AMIDIC DERIVATIVES WITH C-17 AS HIV INHIBITORS
EA201790632A1 (en) 4'-VINYL-SUBSTITUTED DERIVATIVES OF NUCLEOSIDE AS A RNA REPLICATION INHIBITOR INHIBITOR WITH RESPIRATORY SYNCYTAL VIRUS
EA201790778A1 (en) PHARMACEUTICAL COMPOSITIONS OF LONG-TERM ACTION FROM HEPATITIS C
EA201692514A1 (en) PHARMACEUTICAL COMPOSITIONS ON THE BASIS OF SOFOSBUVIR AND RIBAVIRIN WITH MODIFIED FREEDOM
EA201692371A1 (en) 1H-1,8-NAFTYRIDIN-2-ONE AS ANTIPROLIFERATIVE COMPOUNDS